Cardiol Therapeutics Inc. (CRDL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.89 |
| Open | 1.9 |
| Day High | 1.9 |
| Day Low | 1.86 |
| 52-Week High | 2 |
| 52-Week Low | 0.88 |
| Volume | 746,751 |
| Average Volume | 774,290 |
| Market Cap | 214.41M |
| PE | -7.41 |
| EPS | -0.25 |
| Moving Average 50 Days | 1.24 |
| Moving Average 200 Days | 1.15 |
| Change | -0.03 |
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Newsfile
Feb 25, 2026 12:27 PM GMT
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Newsfile
Feb 10, 2026 12:27 PM GMT
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Newsfile
Jan 23, 2026 2:16 PM GMT
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic